QX-001280 / QuantX Biosciences - LARVOL DELTA

A novel, potent DNA polymerase theta inhibitor, QX-001280, demonstrates anti-tumor activity in combination with a PARP1 inhibitor (AACR 2025) - "Combination with a PARP inhibitor, Olaparib, led to significant increase in phosphorylated H2AX indicating that double strand breaks are not being resolved inferring that Pol θ and MMEJ are being inhibited. QX-001280 was well tolerated in all the dose groups.In conclusion, QX-001280 is a potent and specific inhibitor of Polθ which exhibits anti-tumor activity both in vitro and in vivo. It is a high-quality candidate for clinical investigation in combination therapy with PARP inhibitors for cancer treatment."

Combination therapy • Oncology • BRCA • BRCA1 • BRCA2 • POLQ • RAD50